The goal of this study is to establish a cohort of Kaiser Permanente Colorado (KPCO)members who have and have not had COVID-19 infection for serial antibody testing and PCRtesting to: 1. Quantify antibody titers among participants over 9 months. 2. Determine the rates of asymptomatic, mild, and severe recurrent infection among participants with prior COVID-19. 3. Examine association between antibody titer levels and risk of recurrent infection using a case control analysis nested in the cohort.
In this study, the Kaiser Permanente Colorado (KPCO) Institute for Health Research (IHR)
will evaluate SARS-CoV-2 IgG antibody titers over time among individuals with evidence of
prior infection, and correlate antibody titers with risk of recurrent infection. The
investigators will identify KPCO members who have and have not had prior infection,
enroll them into a cohort study, conduct serial surveys for new COVID-19 symptoms, and
facilitate serial viral and antibody testing.
All laboratory testing procedures and clinical management of participants will be
conducted by KPCO operations. The research team will identify participants, obtain
consent, administer surveys to assess COVID-19 symptoms, and direct patients to the
appropriate testing. Health outcomes on cohort participants will be tracked with survey
data on symptoms, clinical and utilization data from the KPCO electronic health record
(e.g., hospitalization), and laboratory data (e.g., viral test results).
This research-operations partnership strategy will generate data to better understand the
implications of positive antibody titers to this novel pathogen.
Inclusion criteria are:
- KPCO health plan members,
- 18 years and older,
- Have a valid email address or phone number in the electronic health record.
Exclusion criterion:
• Being on the Do Not Call List for research.
Kaiser Permanente
Aurora, Colorado, United States
Ingrid Binswanger, MD, MPH, MS, Principal Investigator
Kaiser Permanente